This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis

This study has been terminated.
Wyeth is now a wholly owned subsidiary of Pfizer
Farmades, Italy
Information provided by:
Rennes University Hospital Identifier:
First received: September 16, 2005
Last updated: December 21, 2005
Last verified: September 2005
The aim of the study is to determine whether a therapeutic strategy combining mitoxantrone and interferon beta1b can delay disease progression of at least one point on EDSS scale in patients with clinically very active relapsing-remitting multiple sclerosis.

Condition Intervention Phase
Relapsing-Remitting Multiple Sclerosis Drug: Mitoxantrone Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b

Resource links provided by NLM:

Further study details as provided by Rennes University Hospital:

Primary Outcome Measures:
  • Time to confirmed progression of at least one EDSS point during the 3 years of the study.

Secondary Outcome Measures:
  • - percentage of patients with confirmed progression of at least one point EDSS (confirmed at 3 and 6 months) during the 3 years of the study,
  • - annual rate of relapse;
  • - percentage of relapse-free patients during the study period,
  • - quality of life,
  • - percentage of patients without evidence of disease activity on serial MRIs at months 9, 24 and 36 (number of contrast-enhanced lesions on the annual MRIs, change in lesion burden).

Estimated Enrollment: 124
Study Start Date: July 1999
Estimated Study Completion Date: June 2006

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age : 18-45 years,
  • Clinical disease satisfying the Poser criteria (Amdmt n°4)
  • relapsing-remitting disease (Amdmt N°4)
  • at least 2 exacerbations within the preceding 12 months, having left sequelae,
  • MRI activity at inclusion expressed by at least one gadolinium-enhanced lesion (cranial MRI with 0.1mmol/kg gadolinium),
  • a significant disability at inclusion: EDSS score between 2.5 and 5.5 (Amdt N° 4)
  • written informed consent

Exclusion Criteria:

  • pregnancy and breast-feeding
  • use of an insufficiency effective contraceptive method,
  • general immunosuppressive therapy using cyclophosphamide, mitoxantrone,or total lymphoid irradiation
  • treatment with azathioprine during the 3 months preceding the study
  • clinical relapse or intensive corticosteroid treatment within the 30 days preceding inclusion,
  • associated disease (psychiatric disorder, depressive statenot controlled by appropriate drug therapy, history of heart disease at inclusion examination
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00219908

Hôpital Cote de Nacre
Caen, France, 14033
Hôpital Gabriel Montpied
Clermont-Ferrand, France, 63003
CHU Henri Mondor
Creteil, France, 94000
Hôpital Général
Dijon, France, 21033
CHU Limoges
Limoges, France, 87042
Institut Catholique de Lille
Lomme, France, 59462
Pierre Weitheimer Hospital
Lyon, France, 69394
Chu Timone
Marseille, France, 13385
Centre Guy de Chauliac
Montpellier, France, 34295
CHU Hôpital Central
Nancy, France, 54035
Nice, France, 06000
CHU Pitié-Salpétrière
Paris, France, 75013
Hôpital Saint-Anne
Paris, France, 75014
Centre Fondation Rotschild
Paris, France, 75019
Tenon Hospital
Paris, France, 759170
CHU Strasbourg
Strasbourg, France, 67000
CHU Purpan
Toulouse, France, 31059
Psichiatriche dell'Università di Bari, Policlinico
Bari, Italy, 70122
Dipartimento di Scienze Neurologiche e Psichiatriche
Firenze, Italy, 50134
Hospedal Civile
Gallarate, Italy, 21013
Neuroriabilitazione dell'Università
Genova, Italy, 16132
Fondazionz SAN Raffaele del monte tabor
Milano, Italy, 20132
Clinica Neurologica Università di Torino
Torino, Italy, 10126
Sponsors and Collaborators
Rennes University Hospital
Wyeth is now a wholly owned subsidiary of Pfizer
Farmades, Italy
Study Director: Gilles EDAN, Professor CHU Rennes
  More Information Identifier: NCT00219908     History of Changes
Other Study ID Numbers: 981166
Study First Received: September 16, 2005
Last Updated: December 21, 2005

Keywords provided by Rennes University Hospital:
Multiple sclerosis
Interferon beta1b

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Interferon beta-1b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Adjuvants, Immunologic processed this record on August 18, 2017